Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled adjunctive carisbamate study in Lennox-Gastaut syndrome
MOH_2022-11-06_012164Phase 3Not yet recruiting
- Sponsor
- SK Life Science, Inc.
- Start
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of carisbamate in Lennox-Gastaut syndrome (LGS) (4 arms), sponsored by SK Life Science, Inc. Planned start Oct 2022; status: not yet recruiting.
02
Drugs
carisbamate
03
Conditions
Lennox-Gastaut syndrome (LGS)
Beyond the preview
Go deeper on MOH_2022-11-06_012164.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-11-06_012164.